Starpharma will end the June 2019 quarter with approximately 40.5-41 million dollars in bank
What do we look forward to in this current quarter
*AZD0466 starting phase 1 clinical
*Dep Irinotecan starting phase 1 clinical
*Revenue stream gaining momentum from roll out of VivaGel globally
*Outcome of FDA saga (I believe Starpharma believe there is a chance of not doing additonal clinical trial.....otherwise the company would have began one almost certainly by now) - we should have an update very soon......I am thinking early next week
In regards to China and regulatory approval to distribute condom......this has been going on for nigh for almost 3 years
Below is a background announcement put out by Starpharma in July 2016 Starpharma signs license for a VivaGel® condom in China
Melbourne, Australia; 21 July 2016: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced the signing of an exclusive license and supply agreement with Shenyang Sky and Land Latex Co. Ltd. (Sky and Land) for the manufacture and sale of VivaGel® condoms to the Government segment of the Chinese condom market. This agreement follows the signing of the MOU with Sky and Land in December 2015.
Sky and Land is a diversified Chinese company that owns and operates a number of condom manufacturing plants in China. They are a major provider of condoms to the Chinese Government who provides condoms to its citizens under a number of programs, with an annual requirement of approximately 3 billion condoms.
Under the agreement, Starpharma will supply the VivaGel® active for Sky and Land to manufacture VivaGel®condoms under license specifically for the Chinese Government sector. Starpharma and Sky and Land have already commenced regulatory activities to gain approval of a VivaGel® condom in China.
“This new license in China significantly expands the market opportunity for the VivaGel® condom into a market segment not captured by our current licensees,” said Dr Jackie Fairley, Chief Executive Officer, Starpharma. “The Chinese condom market will grow by nearly 60% in the next five years according to Bloomberg analysis, so access to this important market segment is a major commercial development for Starpharma,” she added.
“Sky and Land is an ideal Chinese partner for this large market given they have both world-class local manufacturing capabilities and a successful history of supplying condoms to the Chinese Government,” Dr Fairley stated.
“Sky and Land is very pleased to be partnering with Starpharma and to be able to provide the world-first antiviral VivaGel® condom to the Chinese Government and people. We look forward to a long and successful partnership for this innovative product,” said Mr Bo Yong Xi, President, Sky and Land.
*Radiotherapeutics collaboration stitched up
*Viral Conjunctivitis collaboration signed
*Option to develop 2nd drug currently in preclinical trials at Starpharma labs taken up by AstraZeneca
*Both Antibody Drug Conjugate non disclosed collaborations becoming agreements with drugs going staight into clinical trials
And of course all the other developments in pipeline progressing
How many fingers and how many pies are Starpharma involved in
Be sure you would need at least two sets of fingers and two sets of toes in total to count all these projects
PS.....we are now getting closer to the proof of concept for 2 internal clinical trials........how many hundreds of millions of dollars will Starpharma be receiving from this............I know.........however Joe Public has really not caught on.......YET!!!
(20min delay)